

**OSELTAMIVIR CAPSULES**  
**DRAFT PROPOSAL FOR**  
***THE INTERNATIONAL PHARMACOPOEIA***  
**(SEPTEMBER 2010)**

***REVISED DRAFT FOR COMMENT***

This document was provided by a quality control expert and was discussed at the recent WHO consultation on specifications for medicines and quality control laboratory issues. Previous comments received have been incorporated into this revised draft. Should you have any comments, please send these to Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or e-mails: [kopps@who.int](mailto:kopps@who.int) with a copy to Ms C. Mendy [mendyc@who.int](mailto:mendyc@who.int) by 29 October 2010.

**If you do not already receive our documents electronically, please let us have your e-mail address (to [bonnyw@who.int](mailto:bonnyw@who.int)) which we will add to our electronic mailing list.**

---

© World Health Organization 2010

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:

Dr Sabine Kopp, Quality Assurance Programme, Medicines Quality Assurance Programme, Quality & Safety: Medicines (QSM), Department of Essential Medicines and Pharmaceutical Policies (EMP), World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; e-mail: [kopps@who.int](mailto:kopps@who.int).

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

**SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/10.363**  
*International Pharmacopoeia monograph on Oseltamivir capsules*

	<b>Date</b>
Preparation of first draft by laboratory	February 2010
Discussion of the draft proposal in the consultation on specifications for medicines and quality control laboratory issues	10-12 May 2010
Mailing of revised draft monograph for comments	July 2010
Collation of comments received	August 2010
Revised draft discussed during video-/teleconference on specifications for medicines	25 August 2010
Revised draft mailed out for comments	October 2010
Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations	18-22 October 2010
Any further action as required	...

## Draft proposal for *The International Pharmacopoeia* (September 2010)

### OSELTAMIVIR CAPSULES

**Category.** Antiviral.

**Storage.** Oseltamivir capsules should be kept in a well closed container, protected from light.

**Labelling.** The designation of the container of Oseltamivir capsules should state that the active ingredient is in the phosphate form and the quantity should be indicated in terms of equivalent amount of oseltamivir.

**Additional information.** Strengths in the current WHO Model list of essential medicines: 30 mg, 45 mg, 75 mg. Strengths in the current WHO Model list of essential medicines for children: 30 mg, 45 mg, 75 mg.

1 mg of oseltamivir is equivalent to approximately 1.3 mg of oseltamivir phosphate.

#### Requirements

Comply with the monograph for "Capsules".

**Definition.** Oseltamivir capsules contain Oseltamivir phosphate. They contain not less than 90.0% and not more than 110.0% of the amount of oseltamivir ( $C_{16}H_{28}N_2O_4$ ) stated on the label.

#### Identity tests

- Either tests A and D or tests B, C and D may be applied
- A. To a quantity of the contents of the capsules containing the equivalent of 20 mg of oseltamivir, add 10 ml of methanol R, shake to dissolve and filter. Evaporate the filtrate to dryness.

Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from oseltamivir phosphate RS or with the *reference spectrum* of oseltamivir phosphate.
- B. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 8 volumes of methanol R, 6 volumes of ethyl acetate R, 4 volumes of toluene R and 2 volumes of ammonia (~ 260 g/l) TS as the mobile phase. Apply separately to the plate 10 µl of each of the following two solutions in methanol R. For solution (A) shake a quantity of the contents of the capsules containing the equivalent of 7.5 mg of oseltamivir with 5 ml, filter and use

the clear filtrate. For solution (B) use 2 mg of oseltamivir phosphate RS per ml. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in air or in a current of cool air. Examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution A corresponds in position, appearance, and intensity to that obtained with solution B.

- C. See the test described under Assay method A. The retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that in the chromatogram obtained with solution (2).
- D. Dissolve a quantity of the contents of the capsules to obtain a solution containing the equivalent of 4 mg of oseltamivir per ml. Neutralize this solution with a few ml of sodium hydroxide (0.1 mol/l) VS. Use 5 ml of the resulting solution; it yields reaction B described under 2.1 General identification tests as characteristic of orthophosphates.

**Related substances.** Carry out the test as described under 1.14.4 High performance liquid chromatography, using the same conditions as under Assay, method A using solutions (1), (3) and (4).

Inject separately 15 µl each of solutions (1), (3), (4) and of the dissolution solvent in the chromatographic system.

Use the chromatogram obtained with solution (4) to identify the peaks due to impurities A, B, C and D. The impurity peaks are eluted at the following relative retention with reference to oseltamivir phosphate (retention time about 19 minutes): impurity A about 0.16, impurity B about 0.17, impurity C about 0.51, impurity D about 0.55 and impurity F about 1.5. The test is not valid unless the resolution between the peaks due to impurities A and B and that between the peaks due to impurities C and D is at least 1.3.

In the chromatogram obtained with solution (1) the area of any peak corresponding to impurity B, when multiplied by a correction factor of 1.4, is not greater than 20 times the area of the peak in the chromatogram obtained with solution (3) (2.0%), the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.6, is not greater than 3 times the area of the peak in the chromatogram obtained with solution (3) (0.3%), the area of any peak corresponding to impurity F is not greater than 5 times the area of the peak in the chromatogram obtained with solution (3) (0.5%), the area of any other peak, apart from the principal peak, is not greater than the area of the peak in the chromatogram obtained with solution (3) (0.1%). The sum of the corrected areas of any peaks corresponding to impurities B or C and of the areas of all other peaks, apart from the principal peak, is not greater than 30 times the area of the peak obtained with solution (3) (3.0%). Disregard any peak with an area less than 0.5 times the area of the principal peak obtained with solution (3) (0.05%).

### Assay

Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with octylsilyl silica gel for chromatography (5 µm)<sup>1</sup>.

---

<sup>1</sup> Waters Symmetry C8 is suitable.

The mobile phase consists of a mixture of 620 volumes of 0.05 M potassium dihydrogen phosphate (adjusted to pH 6 with potassium hydroxide (~ 110 g/l) TS), 245 volumes of methanol R and 135 volumes of acetonitrile R.

Operate with a flow rate of 1.2 ml per minute and the column oven temperature at 50°C. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 207 nm.

Prepare the following solutions in a mixture of 620 volumes of water R, 245 volumes of methanol R and 135 volumes of acetonitrile R (dissolution solvent).

For solution (1) weigh and mix the contents of 20 capsules and transfer a quantity containing the equivalent of 40 mg of oseltamivir, accurately weighed, into a 50-ml volumetric flask. Add about 20 ml of the dissolution solvent, sonicate for about 15 minutes and make up to volume using the dissolution solvent. Filter a portion of this solution through a 0.45 µm filter, discarding the first few ml of the filtrate. For solution (2) dissolve 50 mg of oseltamivir phosphate RS in the dissolution solvent and dilute to 50.0 ml with the same solvent. For solution (3) dilute 1.0 ml of solution (1) to 100 ml with the dissolution solvent and then dilute 1.0 ml of this solution to 10 ml with the same solvent. For solution (4) dissolve about 2 mg of oseltamivir for system suitability RS in the dissolution solvent and dilute to 2 ml with the same solvent.

Inject separately 15 µl each of solutions (1), (2), (4) and of the dissolution solvent in the chromatographic system. Use the chromatogram obtained with solution (4) to identify the peaks due to impurities A, B, C and D. The impurity peaks are eluted at the following relative retention with reference to oseltamivir phosphate (retention time about 19 minutes): impurity A about 0.16, impurity B about 0.17, impurity C about 0.51, impurity D about 0.55 and impurity F about 1.5. The assay is not valid unless the resolution between the peaks due to impurities A and B and that between the peaks due to impurities C and D is at least 1.3.

Measure the areas of the peak responses in the chromatograms obtained with solutions (1) and (2). Calculate the content of oseltamivir ( $C_{16}H_{28}N_2O_4$ ).

**Impurities.** The impurities limited by the requirements of this monograph include those listed in the monograph for Oseltamivir phosphate.

\*\*\*